Journal
Journal for Immunotherapy of Cancer
Publication Date
3-12-2019
Volume
7
Issue
1
First Page
70
Last Page
70
Document Type
Open Access Publication
DOI
10.1186/s40425-019-0538-8
Rights and Permissions
Erbe AK, Wang W, Carmichael L, Hoefges A, Grzywacz B, Reville PK, Ranheim EA, Hank JA, Kim K, Seo S, Mendonca EA, Song Y, Kenkre VP, Hong F, Gascoyne RD, Paietta E, Horning SJ, Miller JS, Kahl B, Sondel PM. Follicular lymphoma patients with KIR2DL2 and KIR3DL1 and their ligands (HLA-C1 and HLA-Bw4) show improved outcome when receiving rituximab. J Immunother Cancer. 2019 Mar 12;7(1):70. doi.org/10.1186/s40425-019-0538-8 https://jitc.bmj.com/content/7/1/70 © The Author(s). Open AccessThis article is distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.
Recommended Citation
Erbe, Amy K; Wang, Wei; Carmichael, Lakeesha; Hoefges, Anna; Grzywacz, Bartosz; Reville, Patrick K; Ranheim, Erik A; Hank, Jacquelyn A; Kim, KyungMann; Seo, Songwon; Mendonca, Eneida A; Song, Yiqiang; Kenkre, Vaishalee P; Hong, Fangxin; Gascoyne, Randy D; Paietta, Elisabeth; Horning, Sandra J; Miller, Jeffrey S; Kahl, Brad; and Sondel, Paul M, "Follicular lymphoma patients with KIR2DL2 and KIR3DL1 and their ligands (HLA-C1 and HLA-Bw4) show improved outcome when receiving rituximab." Journal for Immunotherapy of Cancer. 7, 1. 70 - 70. (2019).
https://digitalcommons.wustl.edu/open_access_pubs/11878
